Patient with acute renal injury presenting dabigatran overdose: Hemodialysis for surgery;Surdosage en dabigatran chez un patient en insuffisance rénale: Intérêt et limites de l'hémodialyse

Annales Francaises d'Anesthesie et de Reanimation

Volumn 33, Issue 1, 2014, Pages 44-46

  Bachellerie, B ^a   Ruiz, S ^a   Conil, J M ^a   Crognier, L ^a   Seguin, T ^a   Georges, B ^a   Fourcade, O ^a  

^a CHU RANGUEIL   (France)

Author keywords

Acute renal injury; Dabigatran; Hemodialysis; Overdose

Indexed keywords

ACUTE RENAL INJURY; DABIGATRAN; HEMODIALYSIS; HÉMODIALYSE; HÉMORRAGIE; INSUFFISANCE RÉNALE AIGUË; OVERDOSE; SURDOSAGE;

ACUTE KIDNEY INJURY; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION DISORDERS; DIABETES MELLITUS, TYPE 2; DRUG OVERDOSE; HEMORRHAGE; HUMANS; HYPERKALEMIA; MALE; NEOPLASMS; PHLEBITIS; RENAL DIALYSIS;

EID: 84894277430     PISSN: 07507658     EISSN: 17696623     Source Type: Journal    
DOI: 10.1016/j.annfar.2013.11.011     Document Type: Article

References (9)

1. Levy J.H., Faraoni D., Spring J.L., Douketis J.D., Samama C.M. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013, 118:1466-1474.
2. Sie P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct: propositions du Groupe d'intérêt en hémostase périopératoire (GIHP) et du Groupe d'études sur l'hémostase et la thrombose (GEHT). Ann Fr Anesth Reanim 2011, 30:645-650.
3. Liesenfeld K.H., Staab A., Hartter S., Formella S., Clemens A., Lehr T. Pharmacometric characterization of dabigatran hemodialysis. Clin Pharmacokinet 2013, 52:453-462.
4. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 2013, 11(Suppl. 1):122-128.
5. Ten Cate H. New oral anticoagulants: discussion on monitoring adherence should start now. Thromb J 2013, 11:8.
6. Marlu R., Hodaj E., Paris A., Albaladejo P., Cracowski J.L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
7. Warkentin T.E., Margetts P., Connolly S.J., Lamy A., Ricci C., Eikelboom J.W. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012, 119:2172-2174.
8. Levi M. Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012, 108:201-202.
9. Chang D.N., Dager W.E., Chin A.I. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013, 61:487-489.